References
- Bailey PC. Medulloblastoma cerebelli: a common type of midcerebellar glioma of childhood. Arch. Neurol. Psychiatry14, 192–224 (1925).
- Pizer B, Clifford S. Medulloblastoma: new insights into biology and treatment. Arch. Dis. Child Educ. Pract. Ed.93(5), 137–144 (2008).
- Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. Radiographics23(6), 1613–1637 (2003).
- Gottardo NG, Gajjar A. Current therapy for medulloblastoma. Curr. Treat. Options Neurol.8(4), 319–334 (2006).
- Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol.6(12), 1073–1085 (2007).
- Rutkowski S, von Hoff K, Emser A et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J. Clin. Oncol.28(33), 4961–4968 (2010).
- Mulhern RK, Reddick WE, Palmer SL et al. Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann. Neurol.46(6), 834–841 (1999).
- Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat. Rev.35(1), 79–96 (2009).
- Srivastava VK, Nalbantoglu J. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics. Cancer Biol. Ther.9(11), 843–852 (2010).
- Parsons DW, Li M, Zhang X et al. The genetic landscape of the childhood cancer medulloblastoma. Science331(6016), 435–439 (2011).
- Gibson P, Tong Y, Robinson G et al. Subtypes of medulloblastoma have distinct developmental origins. Nature468(7327), 1095–1099 (2010).
- Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat. Clin. Pract. Oncol.4(5), 295–304 (2007).
- Gilbertson R, Wickramasinghe C, Hernan R et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br. J. Cancer85(5), 705–712 (2001).
- Northcott PA, Korshunov A, Witt H et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. DOI: 10.1200/JCO.2009.27.4324 (2010) (Epub ahead of print).
- Kool M, Koster J, Bunt J et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One3(8), e3088 (2008).
- Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature415(6870), 436–442 (2002).
- Northcott PA, Rutka JT, Taylor MD. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg. Focus28(1), E6 (2010).
- Thompson MC, Fuller C, Hogg TL et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol.24(12), 1924–1931 (2006).
- Cho YJ, Tsherniak A, Tamayo P et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup That drives poor clinical outcome. J. Clin. Oncol. DOI: 10.1200/JCO.2010.28.5148 (2010) (Epub ahead of print).
- Ellison DW, Kocak M, Dalton J et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J. Clin. Oncol. DOI: 10.1200/JCO.2010.30.2810 (2010) (Epub ahead of print).